Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Abstract
PurposeDespite high tumor mutationburden, immune checkpoint blockade has limited efficacy in SCLC. We hypothesized that poly (ADP-ribose) polymerase inhibition could render SCLC more susceptible to immune checkpoint blockade.MethodsA single-arm, phase II trial (NCT02484404) enrolled patients with relapsed SCLC who received durvalumab, 1500 mg every 4 weeks, and olaparib, 300 mg twice a day. The primary outcome was objective response rate....
Paper Details
Title
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Published Date
Aug 1, 2019
Journal
Volume
14
Issue
8
Pages
1447 - 1457
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History